Literature DB >> 8344359

T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides.

D Kyburz1, P Aichele, D E Speiser, H Hengartner, R M Zinkernagel, H Pircher.   

Abstract

The fate of in vivo activated CD8+ cytotoxic T cells was studied in transgenic mice expressing a T cell receptor (TCR) specific for the lymphocytic choriomeningitis virus (LCMV) glycoprotein peptide 33-41 presented by major histocompatibility complex (MHC) class I molecules. LCMV infection of TCR transgenic mice induced LCMV-specific effector and memory T cells whereas injection of soluble LCMV glycoprotein peptide 33-41 resulted in tolerance by peripheral deletion and anergy of LCMV-specific T cells after an initial expansion phase. Similarly, LCMV peptide 33-41-specific tolerance could be achieved in normal C57BL/6 mice and was not abrogated by an LCMV infection. These results obtained with a classically MHC-restricted peptide antigen parallel previous findings with retroviral or bacterial superantigens and indicate a possibility to modulate specifically mature peripheral cytotoxic T lymphocytes in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344359     DOI: 10.1002/eji.1830230834

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  52 in total

Review 1.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 2.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

3.  Getting peptide vaccines to work: just a matter of quality control?

Authors:  Esteban Celis
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

4.  Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract.

Authors:  Peter M Gray; Subhashini Arimilli; Ellen M Palmer; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 5.  Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation.

Authors:  Matthew F Mescher; Pujya Agarwal; Kerry A Casey; Christopher D Hammerbeck; Zhengguo Xiao; Julie M Curtsinger
Journal:  Semin Immunol       Date:  2007-03-26       Impact factor: 11.130

Review 6.  The anatomy of T-cell activation and tolerance.

Authors:  A Mondino; A Khoruts; M K Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

7.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

8.  Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.

Authors:  P Aichele; D Kyburz; P S Ohashi; B Odermatt; R M Zinkernagel; H Hengartner; H Pircher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

9.  Efficient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC.

Authors:  Marianne M Martinic; Thomas Rülicke; Alana Althage; Bernhard Odermatt; Matthias Höchli; Alain Lamarre; Tilman Dumrese; Daniel E Speiser; Diego Kyburz; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

10.  CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells.

Authors:  Michael G Overstreet; Helen Freyberger; Ian A Cockburn; Yun-Chi Chen; Sze-Wah Tse; Fidel Zavala
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.